Royalty Report: Drugs, Disease – Collection: 274841

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 274841

License Grant
Licensor grants:
—  an exclusive sublicense, with rights to sublicense, under the Licensor Technology to use the Licensor Technology to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory; and
—  an exclusive sublicense, with rights to sublicense, under all rights granted to License pursuant to another Party License agreement to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory.
License Property
Licensor has expertise in the production and oral use of human interferon alpha (IFN) and have proprietary rights and Know-How in the field of production, purification and formulation of IFN.

Product means a formulation or composition containing IFN and designated, detailed, or labeled for oral use in the treatment of the Licensed Indications.

Interferons (IFNs) are a group of signaling proteins made and released by host cells in response to the presence of several viruses. In a typical scenario, a virus-infected cell will release interferons causing nearby cells to heighten their anti-viral defenses.

Field of Use
Licensed Indications means any human indication treated or treatable by the oral administration of IFN, for the treatment of human diseases.

Competing Product means a product for human use that contains IFN and is marketed, distributed or sold in the Territory that is likely to be confused with or used as a substitute for the Product, such confusion and likelihood of substitution being determined based on an analysis of factors such as, but not limited to, recommended dosage, similarity in indications for which it is marketed, distributed or sold, or similarity in tradedress or trademarks used in the marketing, distribution or sale thereof.

Parties are working together to bring a promising new prevention and treatment option for influenza to the developing world.

IPSCIO Record ID: 248386

License Grant
Licensor hereby grants to the Malaysian Licensee:
(a) an exclusive sublicense, with rights to sublicense, under the Licensor Technology to use the Licensor Technology to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory; and
(b) an exclusive sublicense, with rights to sublicense, under all rights granted to Licensor pursuant to the HBL Agreement to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory.
License Property
Product means a formulation or composition containing IFN and designated, detailed, or labeled for oral use in the treatment of the Licensed Indications.

IFN means human interferon alpha.

Licensed Indications means influenza and one other human indication treated or treatable by the oral administration of IFN.

Licensor Technology means the Licensor Patent Rights and the Licensor Know-How.  Licensor Patent Rights means all Patent Rights that are under the Control of Licensor as of the Effective Date and at any time during the Term that are necessary or useful to the use, development, Manufacture, marketing, promotion, distribution, sale and/or commercialization of the Product for use in the treatment of the Licensed Indication, and Improvements thereto developed by or on behalf of Licensor during the Term.

Field of Use
The rights to this grant apply to the healthcare industry relating to influenza and one other human indication treated or treatable by the oral administration.

IPSCIO Record ID: 248341

License Grant
Licensor hereby grants to Licensee of Taiwan:
(a)  an exclusive sublicense, with rights to sublicense, under the Licensor Technology to use the Licensor Technology to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory; and
(b)  an exclusive sublicense, with rights to sublicense, under all rights granted to Licensor pursuant to the HBL Agreement to market, advertise, promote, Manufacture, offer for sale, sell, and distribute the Product in the Territory.
License Property
Product means a formulation or composition containing HBL IFN and designated, detailed, or labeled for oral use in the treatment of the Licensed Indications.

IFN means human interferon alpha.  HBL IFN means the cell culture derived human lymphoblastoid IFN produced by HBL.  

Licensor Technology means the Licensor Patent Rights and the Licensor Know-How.
Licensor Patent Rights means all Patent Rights that are under the Control of Licensor as of the Effective Date under US patent laws’ protection, and at any time during the term that are necessary or useful to the use, development, Manufacture, marketing, promotion, distribution, sale and/or commercialization of the Product for use in the treatment of the Licensed Indications, and Improvements thereto developed by or on behalf of Licensor during the term.

Field of Use
“Licensed Indications” means the human clinical indications of hepatitis B and influenza and one additional human clinical indication.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.